Compare ATOM & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ATOM | ACET |
|---|---|---|
| Founded | 2001 | 1947 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 68.7M | 71.3M |
| IPO Year | 2016 | N/A |
| Metric | ATOM | ACET |
|---|---|---|
| Price | $2.20 | $0.51 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 417.2K | ★ 2.9M |
| Earning Date | 02-10-2026 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $38,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $300.00 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.89 | $0.45 |
| 52 Week High | $17.55 | $1.11 |
| Indicator | ATOM | ACET |
|---|---|---|
| Relative Strength Index (RSI) | 40.34 | 40.57 |
| Support Level | $2.17 | $0.47 |
| Resistance Level | $2.30 | $0.52 |
| Average True Range (ATR) | 0.16 | 0.04 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 13.39 | 34.03 |
Atomera Inc is engaged in the business of developing, commercializing, and licensing proprietary processes and technologies for the semiconductor industry. The company's technology, named Mears Silicon Technology, or MST, is a thin film of re-engineered silicon, typically 100 to 300 angstroms (or approximately 20 to 60 silicon atomic unit cells) thick. MST can be applied as a transistor channel enhancement to CMOS-type transistors, the majority of widely used transistor types in the semiconductor industry. The mears silicon technology of the company can be used for applications like Analog, DRAM, logic and processors, and SRAM.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.